Bristol Myers Squibb gets European Commission nod for Breyanzi for follicular lymphoma Ruchika Sharma16 March 2025 10:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene...
Bristol Myers Squibb Breyanzi gets USFDA nod for Relapsed or Refractory Mantle Cell Lymphoma Ruchika Sharma31 May 2024 2:15 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi (lisocabtagene...
USFDA grants accelerated approval for Bristol Myers Squibb CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Ruchika Sharma16 May 2024 2:30 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for...
Bristol Myers Squibb gets USFDA accelerated nod for Breyanzi as CAR T Cell Therapy for adults with relapsed or refractory chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Susmita Roy15 March 2024 12:32 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...
EU regulator starts safety review of CAR-T cancer cell therapies Ruchika Sharma15 Jan 2024 9:00 AM ISTThe European Union's drug watchdog has said it had started a review into the safety risks associated with cancer cell therapies made by companies such...
Bristol Myers Squibb gets European Commission nod for CAR T Cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy Ruchika Sharma5 May 2023 2:30 PM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb gets positive EMA Committee opinion for Breyanzi for Relapsed or Refractory Large B-cell Lymphoma after one prior therapy Ruchika Sharma2 April 2023 10:00 AM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb wins dismissal of USD 6.4 billion lawsuit over cancer drug delay Ruchika Sharma3 March 2023 2:30 PM ISTNew York: A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers Squibb Co of defrauding investors who stood to receive $6.4 billion had...
GSK, Sanofi, Pfizer and other drugmakers plan to raise prices on at least 350 drugs in US in January Ruchika Sharma31 Dec 2022 1:15 PM ISTTo date, Pfizer announced the most increases, with prices rising on 89 unique drug brands, and an additional increase on 10 drug brands at its Hospira...
Bristol Myers Squibb bags USFDA nod for CAR T Cell Therapy Breyanzi Ruchika Sharma26 Jun 2022 4:00 PM ISTBreyanzi, a differentiated CAR T cell therapy, is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T...
Bristol Myers Squibb must face USD 6.4 billion lawsuit over delayed cancer drug Ruchika Sharma25 Jun 2022 3:30 PM ISTThe case arose from the company's agreement to pay Celgene shareholders holding "contingent value rights" an extra $9 per share in cash if it won U.S....
FDA approves new gene therapy for non-Hodgkin lymphomas Dr. Kamal Kant Kohli6 Feb 2021 4:02 AM ISTThe U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain...
